Crestor Rhabdomyolysis

Adverse reactions from Crestor include Crestor rhabdomyolysis and kidney failure. Crestor Rhabdomyolysis is the breakdown of muscle fibers resulting in the release of muscle fiber contents into the blood circulation which can be toxic to the kidneys and can result in myoglobinuria and kidney damage.

Myoglobin is a damaging oxygen-binding protein pigment found in the skeletal muscle. When the skeletal muscle is damaged, myoglobin is released into the bloodstream. It is filtered out of the bloodstream by the kidneys. Myoglobin breaks down into potentially toxic compounds causing kidney failure. Myoglobinuria symptoms include:

Abnormal urine color (dark, red, or cola colored)
Muscle tenderness
Weakness of the affected muscles
Generalized weakness
Muscle stiffness or aching (myalgia)

Health agencies in Canada and the United Kingdom brought to light seven cases of life-threatening Crestor rhabdomyolysis and nine cases of kidney failure or Crestor kidney damage in patients mostly using lower doses of Crestor.

Pharmaceutical watchdog -- the Public Citizen -- representing 160,000 consumers nationwide petitioned the FDA to immediately remove rosuvastatin (Crestor) from the marketplace before additional cases of life-threatening Crestor rhabdomyolysis, kidney failure and Crestor kidney damage occur.

Also, decisions by a few major U.S. health insurers urged doctors that they would not be reimbursed for Crestor due to the high degree of Crestor rhabdomyolysis risk, hoping to squelch prescriptions. Based on this information, the Public Citizen strongly urged the FDA not to approve Crestor and subsequently advised people not to use the drug once it was approved. The drug also was linked to some cases of Crestor kidney abnormalities not seen with other statins.

Without regard for the Crestor rhabdomyolysis risk, the FDA approved Crestor in August 2003 which had a 2% market share after only three weeks. The manufacturer, AstraZeneca launched an estimated $1 billion first year promotional campaign to persuade doctors to prescribe Crestor, despite the risks of rhabdomyolysis.
Michael Monheit, Esquire
Monheit Law, PC